{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:41:19Z","timestamp":1793418079952,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1111\/jth.15715","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T03:35:45Z","timestamp":1648438545000},"page":"1077-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al\u2010Samkari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15715_bb0010","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT\u2010bleed study","volume":"106","author":"Al\u2010Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"10.1111\/jth.15715_bb0015","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/hae.14034","article-title":"An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"26","author":"Al\u2010Samkari","year":"2020","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15715_bb0020","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.mayocp.2020.03.001","article-title":"Intravenous bevacizumab in hereditary hemorrhagic telangiectasia\u2010related bleeding and high\u2010output cardiac failure: significant inter\u2010individual variability in the need for maintenance therapy","volume":"95","author":"Albitar","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/jth.15715_bb0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia\u2010related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/jth.15715_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188943","article-title":"Intra\u2010venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients","volume":"12","author":"Guilhem","year":"2017","journal-title":"PLoS One"},{"key":"10.1111\/jth.15715_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","article-title":"Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"Buscarini","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/jth.15715_bb0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/0194599818813521","article-title":"Systemic bevacizumab for hereditary hemorrhagic telangiectasia: considerations from observational studies","volume":"160","author":"Al\u2010Samkari","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1111\/jth.15715_bb0045","unstructured":"US FDA. Avastin (Bevacizumab) Prescribing Information. Genentech; 2017."},{"key":"10.1111\/jth.15715_bb0050","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.15715_bb0055","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1111\/jth.15715_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"key":"10.1111\/jth.15715_bb0065","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/rth2.12444","article-title":"A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders","volume":"4","author":"Al\u2010Samkari","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.15715_bb0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2017.03.003","article-title":"Depression and post\u2010traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: a cross\u2010sectional survey","volume":"153","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15715_bb0075","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective","volume":"103","author":"Kritharis","year":"2018","journal-title":"Haematologica"},{"key":"10.1111\/jth.15715_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high\u2010output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"Al\u2010Samkari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/jth.15715_bb0085","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"137","author":"Al\u2010Samkari","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15715_bb0090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al\u2010Samkari","year":"2019","journal-title":"J Intern Med"},{"key":"10.1111\/jth.15715_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1111\/jth.15715_bb0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion\u2010dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"key":"10.1111\/jth.15715_bb0105","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"key":"10.1111\/jth.15715_bb0110","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.4103\/0366-6999.169068","article-title":"Thalidomide effects in patients with hereditary hemorrhagic telangiectasia during therapeutic treatment and in Fli\u2010EGFP transgenic zebrafish model","volume":"128","author":"Peng","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1111\/jth.15715_bb0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0194599817700573","article-title":"Thalidomide for epistaxis in patients with hereditary hemorrhagic telangiectasia: a preliminary study","volume":"157","author":"Fang","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1111\/jth.15715_bb0120","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non\u2010randomised, single\u2010centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.15715_bb0125","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4193\/Rhino14.289","article-title":"Follow\u2010up of thalidomide treatment in patients with hereditary haemorrhagic telangiectasia","volume":"53","author":"Hosman","year":"2015","journal-title":"Rhinology"},{"key":"10.1111\/jth.15715_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4274\/tjh.galenos.2018.2018.0190","article-title":"Thalidomide for the management of bleeding episodes in patients with hereditary hemorrhagic telangiectasia: effects on epistaxis severity score and quality of life","volume":"36","author":"Baysal","year":"2019","journal-title":"Turk J Hematol"},{"key":"10.1111\/jth.15715_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15662","article-title":"North American study for the treatment of recurrent epistaxis with doxycycline: the NOSTRIL trial","author":"McWilliams","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15715_bb0140","series-title":"Thalomid (Thalidomide) Prescribing Information","year":"2021"},{"key":"10.1111\/jth.15715_bb0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V128.22.210.210","article-title":"Pomalidomide in hereditary hemorrhagic telangiectasia: interim results of a phase I study","volume":"128","author":"Samour","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.15715_bb0150","series-title":"Votrient (Pazopanib) Prescribing Information","year":"2021"},{"key":"10.1111\/jth.15715_bb0155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002112","article-title":"Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis","volume":"71","author":"Huber","year":"2007","journal-title":"Kidney Int"},{"key":"10.1111\/jth.15715_bb0160","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr Opin Cell Biol"},{"key":"10.1111\/jth.15715_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1111\/jth.15715_bb0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"10.1111\/jth.15715_bb0175","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.15715_bb0180","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"10.1111\/jth.15715_bb0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.hoc.2019.01.011","article-title":"Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options","volume":"33","author":"Adams","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1111\/jth.15715_bb0190","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/dth.12208","article-title":"Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone","volume":"28","author":"Kim","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1111\/jth.15715_bb0195","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/pbc.24866","article-title":"Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol","volume":"61","author":"Akyuz","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.15715_bb0200","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1542\/peds.2014-3469","article-title":"Sirolimus for the treatment of a massive capillary\u2010lymphatico\u2010venous malformation: a case report","volume":"136","author":"Vlahovic","year":"2015","journal-title":"Pediatrics"},{"key":"10.1111\/jth.15715_bb0205","first-page":"86","article-title":"Sirolimus in the treatment of vascular anomalies","volume":"27","author":"Triana","year":"2017","journal-title":"Eur J Pediatr Surg"},{"key":"10.1111\/jth.15715_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26470","article-title":"Developmental pharmacokinetics of sirolimus: implications for precision dosing in neonates and infants with complicated vascular anomalies","volume":"64","author":"Mizuno","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.15715_bb0215","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15715_bb0220","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1542\/peds.2017-1044","article-title":"Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendothelioma","volume":"141","author":"Russell","year":"2018","journal-title":"Pediatrics"},{"key":"10.1111\/jth.15715_bb0225","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.vaccine.2016.03.001","article-title":"Immunization practices in solid organ transplant recipients","volume":"34","author":"Miyairi","year":"2016","journal-title":"Vaccine"},{"key":"10.1111\/jth.15715_bb0230","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3899\/jrheum.180507","article-title":"Longterm data on sirolimus treatment in patients with lupus nephritis","volume":"45","author":"Yap","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1111\/jth.15715_bb0235","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA\u2010related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"key":"10.1111\/jth.15715_bb0240","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3\u2010kinase alpha\u2010selective inhibition with alpelisib (BYL719) in PIK3CA\u2010altered solid tumors: results from the first\u2010in\u2010human study","volume":"36","author":"Juric","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.15715_bb0245","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/03007995.2021.1900089","article-title":"Selumetinib: the first ever approved drug for neurofibromatosis\u20101 related inoperable plexiform neurofibroma","volume":"37","author":"Mukhopadhyay","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jth.15715_bb0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10637-016-0391-2","article-title":"A phase I dose\u2010escalation study of TAK\u2010733, an investigational oral MEK inhibitor, in patients with advanced solid tumors","volume":"35","author":"Adjei","year":"2017","journal-title":"Invest New Drugs"},{"issue":"01","key":"10.1111\/jth.15715_bb0255","first-page":"052","article-title":"Treatment of plexiform neurofibromas with MEK inhibitors: first results with a new therapeutic option","volume":"53","author":"Vaassen","year":"2021","journal-title":"Neuropediatrics"},{"key":"10.1111\/jth.15715_bb0260","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJMoa1709449","article-title":"Somatic activating KRAS mutations in arteriovenous malformations of the brain","volume":"378","author":"Nikolaev","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15715_bb0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/brain\/awy307","article-title":"High prevalence of KRAS\/BRAF somatic mutations in brain and spinal cord arteriovenous malformations","volume":"142","author":"Hong","year":"2019","journal-title":"Brain"},{"key":"10.1111\/jth.15715_bb0270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ajhg.2016.06.010","article-title":"GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation","volume":"99","author":"Lim","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1111\/jth.15715_bb0275","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1172\/JCI98589","article-title":"Mosaic RAS\/MAPK variants cause sporadic vascular malformations which respond to targeted therapy","volume":"128","author":"Al\u2010Olabi","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.15715_bb0280","series-title":"Discovery and Characterization of RASopathy Mutations Underlying Lymphatic Anomalies and Preparation for Clinical Development","author":"Li","year":"2020"},{"key":"10.1111\/jth.15715_bb0285","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat Med"},{"key":"10.1111\/jth.15715_bb0290","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ajhg.2017.01.018","article-title":"Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation","volume":"100","author":"Couto","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1111\/jth.15715_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226852","article-title":"Somatic mutations in intracranial arteriovenous malformations","volume":"14","author":"Goss","year":"2019","journal-title":"PLoS One"},{"key":"10.1111\/jth.15715_bb0300","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10456-019-09678-w","article-title":"Intramuscular fast\u2010flow vascular anomaly contains somatic MAP2K1 and KRAS mutations","volume":"22","author":"Goss","year":"2019","journal-title":"Angiogenesis"},{"key":"10.1111\/jth.15715_bb0305","series-title":"Trametinib as a promising therapeutic option for treating vascular lesions in a novel arteriovenous malformation mouse model","author":"Nguyen","year":"2020"},{"key":"10.1111\/jth.15715_bb0310","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamadermatol.2018.4653","article-title":"Genotype\u2010guided medical treatment of an arteriovenous malformation in a child","volume":"155","author":"Lekwuttikarn","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1111\/jth.15715_bb0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF\u2010mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:34:47Z","timestamp":1761536087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622001817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1538783622001817"],"URL":"https:\/\/doi.org\/10.1111\/jth.15715","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}